GlaxoSmithKline Pharmaceuticals Limited (GLAXO) reports Q2 FY27 growth, driven by portfolio transformation and innovation.
Zydus Lifesciences Limited (ZYDUSLIFE) reports a 29% YoY revenue surge in Q2 FY27, driven by strong performance across its segments.
Amanta Healthcare Limited (AMANTA) announces Q2 & H1FY27 results with revenue up 17% YoY, PAT growth at 26%, and new capacity expansions.
Lupin Limited reported Q2 FY2027 results with sales up 14% YoY, but PAT down 22%. Key highlights include strong growth in key markets.
Vijaya Diagnostic Centre Limited (NSE: VIJAYA) reports Q2 & H1 FY27 results with 26.7% YoY revenue growth, driven by strong operational performance.
Laxmi Dental Limited (LAXMIDENTL) reports Q2 FY27 results with a 10% revenue increase, strong EBITDA and PAT margins.
Metropolis Healthcare Limited (METROPOLIS) reports strong Q2 FY27 performance with revenue up 16% to ₹497 crore and PAT up 43%.
Nephrocare Health Services Limited reports Q2 FY27 results with revenue up 23.6% YoY and PAT growing 34.7%.
Anthem Biosciences Limited (NSE: ANTHEM) reports strong Q2 & H1 FY27 results with consolidated revenue up 7.2% and EBITDA margins at 50.6%.
Global Health Limited (MEDANTA) reports a 33.6% y-o-y revenue growth and a 38.3% surge in PAT for Q2 FY27.